Unbiased Analysis of Today's Healthcare Issues
Excited to be attending ISPOR 2026 next week. I’m looking forward to some great plenary sessions, presenting my research on “The Extent of Treatment Response and Preference Heterogeneity in Major Depressive Disorder: Implications for Population-Level Resource Allocation” with co-authors Nadine Zawadzki and Cheryl Neslusan, and meeting up with old colleagues. See you in Philadelphia!
That is the title of my Fast Facts presentation at ISPOR Europe at 11:30 GMT on Tuesday, November 11 with Tiago Beck. If you’re in Glasgow next week, feel free to stop by this session. Should be interesting. The abstract is below. As trilogue negotiations on the EU pharmaceutical package progress, stakeholders across the healthcare…
ISPOR recently released their award winners from their 2025 conference this May. Winners are listed below. I’m excited to announce that my podium presentation “Quantifying Treatment Value Using Alternative Health Benefit Metrics: A Case Study of Adjuvant Osimertinib for Elderly Patients with EGFR mutated NSCLC Following Resection” received an award for the Best General Podium…
Three panels. One great city. Can’t wait for the conversations at ISPOR 2024 in Montréal. GCEA: Where do we go from here? (14 May, 5-6pm) Should we finally rethink the 3% discount rate? (15 May, 3:15-4:15pm) How can HEOR support providers in value-based care? (16 May, 10-11am) I’ll be diving into all three — including teaming…
Who won the ISPOR’s 2024 HEOR awards? The list is below. Avedis Donabedian Lifetime Achievement Award: C. Daniel Mullins, PhD; Professor of Practice, Sciences, and Health Outcomes Research and Executive Director of The PATIENTS Program; University of Maryland School of Pharmacy; Baltimore, MD, USA Marilyn Dix Smith Leadership Award: Deborah Marshall, PhD; Professor and Svare…
I will be speaking on two panels at the upcoming ISPOR 2024 conference in Atlanta, GA. Myfirst panel “Economic Insights Into Nutrition: Unlocking the Value in Chronic Disease Management” on Tuesday, May 7, will discuss the opportunities and challenges of economic evaluation of nutrition interventions and compare economic analysis of nutrition interventions with analysis of…
These trends are summarized on their webpage and in a larger report. Here they are with some key excerpts from their report: Real world Evidence. “As RWE continues to gain significant traction in healthcare, agencies including the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), The National Institute for Health and…
As heard at ISPOR 2023 in Boston: On high US drug prices: “My hope as a European is that US never gets its health system in order.” And his Yoda-like pronouncement: “Affordability is important; but value is critical” Michael Drummond HT: Peter Neumann. See also Dr. Neumann’s ISPOR recap thread
If you’re attending the ISPOR 2023 conference in Boston, MA please feel free to come by view some of my research. This includes the following: Podium Presentation #108: Economic Evaluations of Rare Diseases: “Quantifying the Insurance and Altruism Value for Rare Diseases: A Case Study for Duchenne Muscular Dystrophy”. Jason Shafrin will be presenting this work as…
Clinical trials have detailed study protocols and are registered on ClinicalTrials.gov. What level of details are needed for real-world data (RWD) analyses that aim to estimate treatment effects? In Europe, the European Medicines Agency (EMA) requires registration of many study protocols using a template for observational post-authorization safety studies (PASS) conducted by marketing authorization holders.…